生物活性：Palonosetron-d3 (hydrochloride) is the deuterium labeled Palonosetron hydrochloride. Palonosetron hydrochloride is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV)[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Palonosetron-d3 hydrochloride 相关抗体:
MTNR1A Antibody
分子量：335.89
Formula：C19H22D3ClN2O
CAS 号：1246816-81-8
非标记 CAS：135729-62-3
中文名称：盐酸帕洛诺司琼 d3 (盐酸盐)
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (559 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Vishnu Murthy M, Srinivas K, Kumar R, Mukkanti K.
Development and validation of a stability-indicating LC method for determining palonosetron hydrochloride, its related compounds and degradation products using naphthalethyl stationary phase.
J Pharm Biomed Anal. 2011 Sep 10;56(2):429-35.
 [Content Brief]
[3]. Ajioka H, Morita F, Akizawa Y, Yoshida K, Kitamura R, Takimoto H.
Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist.Nihon Yakurigaku Zasshi. 2010 Aug;136(2):113-20.
 [Content Brief]
[4]. Ruhlmann C, Herrstedt J.
Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48.
 [Content Brief]
[5]. Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.
Am J Health Syst Pharm. 2007 Jun 1;64(11):1209-13.
 [Content Brief]
[6]. Clark, Robin D.; Miller, Aaron B.; Berger, Jacob; Repke, David B.; Weinhardt, Klaus K.; Kowalczyk, Bruce A.; Eglen, Richard M.; Bonhaus, Douglas W.; Lee, Chi Ho; et al.2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.J. Med. Chem., 1993, 36 (18), pp 2645-2657